At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 82 enrolled
Drug / intervention
EDP-938 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)
In Brief
A Phase 2 clinical trial evaluating EDP-938 and Placebo for Respiratory Syncytial Virus. Completed, enrolled 82 participants across 29 sites in 7 countries.
Detailed Summary
This was a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus
CountriesArgentina, Bulgaria, New Zealand, Poland, South Africa, Ukraine, United States
CollaboratorsPPD Development, LP
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartJan 2020
Primary CompletionJan 2022
TodayJul 2026
First PostedDec 12, 2019
Enrollment StartJan 22, 2020
Primary CompletionJan 4, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.6 years ago
Interventions
EDP-938drug
Four tablets daily for 5 days
Placebodrug
Four tablets daily for 5 days